



PREVALENCE OF CANDIDEMIA PATIENTS IN ICU IN A TERTIARY CARE HOSPITAL

Microbiology

Dr. Shuvi Sharan* Assistant Professor, Department of Microbiology, Madhubani Medical College and Hospital (MMCH), Madhubani, Bihar. *Corresponding Author

Dr. Jagat Narayan Nayak Associate Professor, Department of Microbiology, Madhubani Medical College and Hospital (MMCH), Madhubani, Bihar.

ABSTRACT

The incidence of candidemia, despite under-reporting, is rising worldwide, species distribution in recent years shifting from *Candida albicans* towards non-*albicans* species, with increasing resistance to antifungal drugs, especially the azoles.

Aim of this study was to determine the current prevalence of candidemia among patients admitted to ICU and antifungal resistance profile to help the clinicians to develop an empirical antifungal therapy in this region. A prospective observational study was conducted on a total of 75 patients admitted to the ICU of Madhubani Medical College and Hospital, Madhubani, Bihar over 12-month period and screened for the presence of candidemia by performing blood cultures. The prevalence of candidemia among ICU patients with features of SIRS was 16% (n=12) in our study. *Candida albicans* with six isolates was the commonest species (50%) isolated from candidemic patients (n=12), followed by *C. glabrata* with three isolates (25%) and *C. krusei* with two (16.6%). The least common species in our study was *C. tropicalis* (8.3%) with only one isolate.

Results of this study make it clear that routine screening of *Candida* isolates to the species level followed by confirmation of resistant strains by antifungal susceptibility testing is essential, and could assist clinicians in developing important prophylactic and treatment guidelines for improved management.

KEYWORDS

Antifungal drug resistance, Candidemia, *Candida albicans*, non-*albicans* *Candida*

INTRODUCTION

Candida spp. are the most common cause of opportunistic fungal infections worldwide.^[1] *Candida* are generally a part of normal microbial flora of skin and mucous membrane in immunocompetent individuals but may cause severe systemic infections in critically ill patients with underlying disease such as diabetes mellitus, prolonged duration of stay in ICU, or other factors which may suppress the immunity.^[2] They causes a wide variety of infections, ranging from mild mucocutaneous to severe invasive infections that can involve virtually any organ.^[3] Approximately 200 *Candida* spp. are known till date, of which about 10 % are recognized to cause infections in human, most commonly by *Candida albicans*.^[4]

The term Candidemia describes the presence of *Candida* spp in blood stream. It is a life-threatening fungal infection associated with a mortality rate of 38%. It also prolongs hospital stays by as much as 30 days and increases the cost of medical care.^[5]

Candida spp. is one of the most common causes of bloodstream infection among the patients admitted in the intensive care unit (ICU).^[6,7] Although *Candida albicans* remains the most prevalent species, there has been a clear shift towards non-*albicans* species namely *Candida tropicalis*, *Candida parapsilosis*, *Candida krusei* particularly found in the neutropenic patient and *Candida glabrata* found especially in patients with solid tumor.^[7-9]

Several retrospective studies have demonstrated that a number of predisposing factors are responsible for spread of *Candida* infections in the ICU.^[10-12] The commonly associated factors are total parenteral nutrition (TPN), use of multiple broad spectrum antibiotics, major surgeries, central venous catheter insertion, urinary catheter, mechanical ventilation, persistent neutropenia, renal failure, glucocorticosteroid treatment, burns, and hemodialysis.^[13]

Preexposure to antifungals particularly azoles, mostly in the form of prophylaxis, and to a lesser extent with echinocandins, have been associated with the occurrence of breakthrough infections with resistant *Candida* species. Although *C. glabrata* and *C. krusei* have been the predominant isolates in these settings, other resistant non-*albicans* *Candida* species are being increasingly observed.^[14,15]

The increasing incidence of candidemia due to non-*albicans* species in different regions of country and emergence of antifungal resistance due to irrational use of drugs necessitates the formulation of empirical therapy for treatment of patients suffering from candidemia and antifungal prophylaxis for patients at risk of developing the infection.^[16,17]

MATERIAL AND METHODS

The study was a prospective, observational and non-interventional study carried out in Department of Microbiology, Madhubani Medical College and Hospital, Madhubani, Bihar over a period 12-month from May 2019 to April 2020. Seventy five clinically suspected cases of systemic inflammatory response syndrome (SIRS) patients, with more than 48 hours duration of stay in ICU were included in the study. A written informed consent was obtained from the patient and/or from blood relatives. Patient's clinical and epidemiological information was recorded on pre-defined questionnaire.

Single blood specimen of 8-10 ml were collected aseptically from each patient and inoculated in proprietary fungal blood culture bottle and incubated in an automated blood culture detection system (BACTEC 9050). Bottles were incubated for up to 14 days before being reported negative. Broth from positive bottles was smeared and Gram-stained, and sub-cultured on Sabouraud's Dextrose Agar (SDA) medium and incubated aerobically at 37°C for 24-48 hours. *Candida* isolates, characterized by smooth, creamy and pasty appearance of colonies on SDA, were subjected to speciation by Germ tube test, Sugar fermentation test, Sugar assimilation test, morphological characters on Corn meal agar with 1% Tween 80 (CMA) and colour production on CHROM agar media. An episode of candidemia was identified when the *Candida* was isolated from the blood culture of the patient.

The recovered *Candida* isolates were then subjected to antifungal susceptibility testing by broth microdilution method using sterile, disposable, multiwell microdilution plates (96 U shaped well) as per standard CLSI guidelines (M27-A3).^[18] Antifungal susceptibility testing was done for Voriconazole, Fluconazole, Ketoconazole and Amphotericin B. The concentration gradient used for voriconazole was 0.125 to 64 mg/litre, whereas for fluconazole, ketoconazole and amphotericin B was 0.0313 to 16 mg/litre. The broth medium used for the test was RPMI 1640. The endpoints were read visually by naked eyes.

The turbidity was graded from 0 to 4 with 0 indicating optically clear and 4 indicating no reduction in turbidity compared to the turbidity of the drug-free control well. For amphotericin B, the endpoint was the lowest concentration that inhibits visual growth or an endpoint score of 0. The endpoint for the azoles was the concentration where there was a decrease in turbidity of approximately 50% or an endpoint score of 2. The control strains used were *C. albicans* ATCC- 5314 and *C. krusei* ATCC- 6258.

Data was analyzed for statistical significance between various sub-groups within the study population by using IBM SPSS statistics

version 21. Mean, median and standard deviation were calculated as per standard definition. P value <0.05 was taken as level of significance.

RESULTS

A total of 75 patients, suspected of sepsis, admitted in the ICU were included during the study period. Twelve out of 75 patients were positive for candidemia with prevalence rate of 16 %. Out of 75 patients, culture was positive in 28 (37.3%) patients which were confirmed as cases of sepsis.

Among these 28 isolates, 16 (57.1%) were aerobic bacterial pathogens and 12 (42.9%) were organisms belonging to *Candida* species.

Table 1 demonstrates that majority of patients in the study group comprised of males (n=57, 76%). The male to female ratio was 3.2:1. Out of 57 male patients, 7 (12.3%) had candidemia, whereas 5 (27.7%) out of 18 female patients had candidemia.

Culture positivity among males and females was insignificant in the study (p=0.145). Out of 75 patients the maximum number of patients were in the age group of 60-69 years (n=17, 22.6%) followed by patients (n=14, 18.6%) in 40-49 years age group.

Table 1 : Gender Wise Distribution Of Patients With And Without Candidemia

Gender	Candidemia present (n=12)	Candidemia absent (n=63)
Males (n=57)	7	50
Females (n=18)	5	13

Table 2 shows the distribution of *Candida* species among culture positive patients. *C. albicans* was found to be the commonest species isolated (n=6, 50%). Among non *albicans*, *C. glabrata* predominated being (n=3, 25%) following which, *C. krusei* (n=2, 16.6%) and *C. tropicalis* (n=1, 8.3%) were recovered.

Table 2 : Distribution Of Candida Species Isolates Recovered From Blood

Candida Species	No. of cases (n=12)	Percentage (%)
<i>Candida albicans</i>	6	50%
<i>Candida glabrata</i>	3	25%
<i>Candida Krusei</i>	2	16.67%
<i>Candida tropicalis</i>	1	8.33%

Table 3 shows out of 6 *Candida albicans* isolates, there was 33.3% resistance to fluconazole and ketoconazole and 16.7% resistance to voriconazole. Whereas among non *albicans*, none of the isolates of *Candida glabrata* was resistant to amphotericin B (0%) and 33.33% were resistant to voriconazole whereas 2 isolates (66.6%) were resistant to fluconazole and ketoconazole. *C. tropicalis* was sensitive to all the drugs. *C. krusei* due to their intrinsically resistant properties, sensitivity to fluconazole was not reported. None of the isolates of *C. krusei* were resistant to amphotericin B (100%) and 50% were resistant to ketoconazole and voriconazole.

Thus, no resistance to amphotericin B was observed in our isolates whereas 25% resistance to voriconazole, 41.7% to ketoconazole and 50% resistance to fluconazole was observed.

Table 3 : Antifungal Resistance Pattern Of Culture Positive Isolates

Candida species	No. of cases (n=12)	Resistance (%)			
		Fluconazole	Ketoconazole	Voriconazole	Amphotericin B
<i>C. albicans</i>	6	2(33.33%)	2(33.33%)	1(16.67%)	0(0%)
<i>C. glabrata</i>	3	2(66.66%)	2(66.66%)	1(33.33%)	0(0%)
<i>C. tropicalis</i>	1	0(0%)	0(0%)	0(0%)	0(0%)
<i>C. Krusei</i>	2	-	1(50%)	1(50%)	0(0%)
Total	12	6(50%)	5(41.7%)	3(25%)	0(0%)

As shown by table 4, 33.33% of *Candida albicans* were resistant to fluconazole and ketoconazole whereas only 66.66% non *albicans* *Candida* were resistant to fluconazole and 50 % to Ketoconazole respectively. There was 16.7% and 33.3% resistance to voriconazole among *albicans* and non *albicans* *Candida* respectively. But there was no difference in sensitivity to amphotericin B as all the isolates were sensitive to it.

Table 4 : Comparison Of Antifungal Susceptibility Of Albicans And Non-albicans Candida

Isolates	Number (%)	Resistance (%)			
		Fluconazole	Ketoconazole	Voriconazole	Amphotericin B
<i>Candida albicans</i>	6(50%)	2(33.33%)	2(33.33%)	1(16.67%)	0(0%)
Non- <i>albicans</i> <i>Candida</i>	6(50%)	4(66.67%)	3(50%)	2(33.33%)	0(0%)
p-value		0.24	0.24	0.18	1

All the 12 patients with candidemia were treated with antifungals and out of 12, 9 patients died with mortality being 75%, although direct correlation of candidemia as the cause of death in any of the patients could not be ascertained due to multiple underlying pathologies.

DISCUSSION

Candidemia in critically ill patients is usually a severe and life-threatening condition and is difficult to diagnose leading to delayed treatment, prolonged hospitalization, increased health care costs, and more importantly, increased morbidity and mortality.^[19] *Candida* has emerged as an important cause of nosocomial blood stream infection. But, the actual prevalence of candidemia in India is lacking due to unavailability of sufficient data from various parts of the country. However, a study from Lucknow reported an incidence rate of 1.61 per 1000 hospital admissions for candidemia.^[20] A New Delhi based study gave a prevalence rate of 18% while a study in South India reported an incidence rate of 5.7% for candidemia.^[21,22] A study by Sahni et al. from Maulana Azad Medical College, New Delhi, found an incidence rate of 6.9% for *Candida* species in BSI.^[23] Our study reported a prevalence rate of 16% for candidemia in ICU. These studies suggest wide variations in the prevalence of candidemia in different geographical location of India.

In the present study the age of recruited patients ranged from 20 to 88 years. The largest percentage of patients was found in the 60-69 year age group (22.6 %), followed by patients in the age groups of 40-49 and 20-29 years. Similar findings have been reported in studies by Leon et al. who reported a mean age of 60 (±17) years and Laupland et al. reported a mean age of 57.8 years in their 5-year study of invasive *Candida* infections.^[24,25] Gonzalez de Molina et al. reported a mean age of 59 (±17.9) years in their study of mortality attributable to candidemia in critically ill patients. Candidemia is well-known for affecting the extremes of age, possibly due to the immaturity of the immune system in children, and the waning of the immune response in the elderly. But the majority of patients in our study were middle-aged, possible reasons for this might be the overrepresentation of middle-aged people among patients admitted to our ICU.

Male patients outnumbered females in our study with a male to female ratio of 3.2:1; similar findings have been seen in other studies across the world. Leroy et al. reported a male to female ratio of 3.08:1 in their evaluation of the *Candida*-score in critically ill patients. Ylipalosaari et al. reported a male to female ratio of 2.4:1 in their study of the epidemiology and risk factors for candidemia in an ICU setting.

The male to female ratio among culture-positive patients in our study was 1.4:1, which is similar to the corresponding figure of 1.7:1 reported by Gonzalez de Molina et al. Another study by Leon et al. reported a male to female ratio 1.89:1 in culture-positive.^[24] The male preponderance seen among culture-positive patients in all these studies was corroborated by the findings of our study.

Geographical variation is recognized to be an important feature in the species distribution of *Candida*. In sync with trends observed in the majority of studies from around the globe, a shift in the species distribution of *Candida* from *albicans* to non *albicans* has been noted in several major Indian hospitals. The authors all over the world have noted a strong correlation of the rise in non-*albicans* species with the use of fluconazole. However in our study, *C. albicans* with six isolates was the commonest species (50%) isolated from candidemic patients (n=12), followed by *C. glabrata* with three isolates (25%), *C. krusei* with two (16.6%) and the least common species being *C. tropicalis* (8.3%) with only one isolate. This could be accounted for by the fact that prophylactic use of fluconazole is not a standard practice in our ICU and none of the patients recruited in this study were receiving antifungal prophylaxis.

Similar findings have been reported by many authors across the world. In the SENTRY surveillance programme conducted between 1997-2000, *C. albicans* accounted for 50% of isolates, while the same species comprised 71% of all *Candida* isolates in a study by Yamamura et al from Canada. The percentages of *albicans* and non-*albicans* species *Candida* were equal (50%) in our study. Leroy et al reported similar findings with 53% of *C. albicans* and 47 % of non-*albicans* species in their study. In contrast, Dimopoulos et al reported a higher percentage (64.3%) of *C. albicans* than non *albicans* species. Kett et al reported regional variations in the relative abundance of *C. albicans* and other *Candida* species. According to their study on *Candida* blood stream infections in ICUs, *C. albicans* accounted for 72.7%, 100%, and 68.8% of *Candida* isolates in Asia, Russia & Pacific, and North America respectively.

Our study also reiterates the regional variation in distribution of *Candida* species in ICUs of different tertiary care hospitals.

In our study, 33.3% of *C. albicans* were resistant to fluconazole and ketoconazole, 16.7% to voriconazole and none to amphotericin B. Similar high level of resistance had been reported by Kotwal et al.[29] Another study by Kothari et al reported resistance to fluconazole among 42% of isolates of *C. albicans*. This is in contrast to low rate of resistance (5%) to fluconazole among isolates of *C. albicans* reported by Pfaller et al, in their study on ICU patients. Similarly the ARTEMIS DISK global antifungal susceptibility surveillance study conducted over a period of 10.5 years reported only 2% resistance to fluconazole among *C. albicans* isolates.

The reason for this difference remains unknown; this could be an interesting regional characteristic if this finding is validated in future studies. The intrinsic and emerging resistance to azoles actually represents a major challenge for empirical, therapeutic and prophylactic strategies.

Among non-*albicans Candida* species isolated in our study, *C. glabrata* showed a very high rate (66.6%) of resistance to fluconazole and ketoconazole.

This is similar to data published in recent years in which azole resistance has been found to be higher among *C. glabrata*. In a Scottish study, among the isolates of candidemia, 55% of *C. glabrata* isolates showed reduced susceptibility to fluconazole, but azole resistance among other species of *Candida* was extremely low. Similarly, Tan et al observed relatively higher fluconazole resistance among *C. glabrata* isolates. Our lone isolate of *C. tropicalis* was sensitive to all drugs tested. In contrast, Chakrabarti et al reported resistance rates of 10.2 to 13.6 % to azoles in *C. tropicalis*. This discrepancy in sensitivity pattern can be explained by the fact that only one isolate of *C. tropicalis* recovered in our study. The overall prevalence of resistance to voriconazole, ketoconazole and fluconazole was 25 %, 42 % and 50 % respectively among our *Candida* isolates. No isolate of ours was resistant to amphotericin B. Kothari et al also found the smallest percentage of their isolates (8%) to be resistant to amphotericin B, followed by 44% to voriconazole and 64% to fluconazole.^[21] Resistance to amphotericin B is attributable to the reduction in ergosterol in resistant mutants of *Candida*. Such cases have been reported from immunocompromised patients who have received extensive antifungal agents and broadspectrum antimicrobials.

In the ICU, there is usually a failure of host defense mechanisms and also complications associated with the patients underlying disease. Therefore, mortality is not solely related to the pathogenicity of the *Candida* species. In this study, mortality in patients presenting with candidemia was high (75%), but direct correlation of candidemia and mortality could not be ascertained. Barberino et al. suggest that invasive candidiasis is a better marker for disease severity than an independent risk factor for mortality during the course of infection.

Candidemia is emerging as a significant problem in hospitalized patients especially in ICU setup. A gradual but significant epidemiological shift to higher isolation of non-*albicans Candida* species is being noticed, with high rates of azole resistance.

Based on the present results, it is clear that routine screening of *Candida* isolates to the species level followed by confirmation of resistant strains by antifungal susceptibility testing is essential, and could assist clinicians in promoting adoption of important

prophylactic and treatment guidelines for its improved management. Moreover, continued surveillance of candidemia is important to document changes in its epidemiological features and antifungal susceptibilities.

REFERENCES

- Achkar JM, Fries BC. *Candida* Infections of the Genitourinary Tract. *Clin Microbiol Rev* 2010; 23: 253-73.
- Vincent JL. *Candida* infections in surgical intensive care unit patients. In: Holzheimer RG, Mannick JA, editors. *Surgical Treatment: Evidence-Based and Problem-Oriented*. Munich: Zuckschwerdt; 2001. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK6999/>.
- Asmundsdottir LR, Erlendsson H, Gottfredsson M. Increasing incidence of Candidemia: Results from a 20 Year Nationwide study in Iceland. *J Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis* 2010; 10: 312.
- Poikonen E, Lyytikäinen O, Anttila VJ, Koivula I, Lumio J, Kotilainen P, et al. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. *BMC Infect Dis* 2010; 10: 312.
- Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital acquired candidemia. The attributable mortality and excess length of stay. *Arch Intern Med* 1988; 148: 2642-45.
- Chander J, Singla N, Sidhu SK, Gombar S. Epidemiology of *Candida* blood stream infections: experience of a tertiary care centre in North India. *J Infect Dev Ctries* 2013; 7: 670-5.
- Eggimann P, Garbino J, Pittet D. Epidemiology of *Candida* species infections in critically ill nonimmunosuppressed patients. *Lancet Infect Dis* 2003; 3: 685-702.
- Leleu G, Aegerter P, Guidet B. Systemic candidiasis in intensive care units: A multicentre, matched cohort study. *J Crit Care* 2002; 17: 168-75.
- Passwan AK, Raju DC, Singh DK, Khuba S, Dubey RK. Isolation and distribution of *Candida* species among different clinical situations in critically ill patients: prospective study. *Int J Biomed Res* 2012; 3: 120-6.
- Méan M, Marchetti O, Calandra T. Bench-to-bedside review: *Candida* infections in the intensive care unit. *Crit Care* 2008; 12: 204.
- Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. *Clin Microbiol Rev* 2007; 20: 133-63.
- Lagrou K, Verhaegen J, Peetermans WE, De RT, Maertens J, Van WE. Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species. *Eur J Clin Microbiol Infect Dis* 2007; 26: 541-7.
- Kibbler CC. Fungaemia and disseminated fungal infection. In: Kibbler CC, Mackenzie DWR, Odds FC, editors. *Principles and practice of clinical mycology*. John Wiley & Sons Ltd; Chichester, England: 1996.
- Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: *Candida glabrata* and *Candida krusei* as the leading causes of candidemia in hematologic malignancy. *Cancer* 2008; 112: 2493-99.
- Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. *Cancer* 2009; 115: 4745-52.
- Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive *Candida* species infections. *J Antimicrob Chemother* 2007; 60: 613-8.
- Armstrong JD. Invasive *Candida* species infection: the importance of adequate empirical antifungal therapy. *J Antimicrob Chemother* 2007; 60: 459-60.
- Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, 3rd ed., M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA, 2008.
- Bassetti M, Mikulska M, Viscoli C. Bench to bedside review: therapeutic management of invasive candidiasis in the intensive care unit. *Crit Care* 2010; 14: 244.
- Verma AK, Prasad KN, Singh M, Dixit AK, Ayyagari A. Candidaemia in patients of a tertiary health care hospital from north India. *Indian J Med Res* 2003; 117: 122-8.
- Kothari A, Sagar V. Epidemiology of *Candida* bloodstream infections in a tertiary care institute in India. *Indian J Med Microbiol* 2008; 27: 171-2.
- Kumar CP, Sundararajan T, Menon T, Venkateshikulu M. Candidiasis in children with onco-hematological diseases in Chennai, south India. *Jpn J Infect Dis* 2005; 58: 218-21.
- Sahni V, Agarwal SK, Singh NP, Anuradha S, Sikdar S, Wadhwa A, et al. Candidemia - an under-recognized nosocomial infection in Indian Hospitals. *J Assoc Physicians India* 2005; 53: 607-11.
- León C, Ruiz-Santana S, Saavedra P, Galván B, Blanco A, Castro C, et al. Usefulness of the *Candida* score for discriminating between *Candida* colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. *Crit Care Med* 2009; 37: 1624-33.
- Laupland KB, Gregson DB, Church DL, Ross T, Elsayed S. Invasive *Candida* species infections: a 5 year population-based assessment. *J Antimicrob Chemother* 2000; 56: 532-7.